Zealand Pharma AS (Zealand) is a biotechnology company that discovers and develops peptide-based medicines. The company's pipeline products include liraglutide, a long-acting GLP-2 analog in development for the treatment of short bowel syndrome; dasiglucagon for congenital hyperinsulinism and bi-hormonal artificial pancreas systems; survodutide (BI 456906) treats obesity and nonalcoholic steatohepatitis; ZP8396 for overweight and obesity; dapiglutide for obesity. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. Zealand is headquartered in Soeborg, Denmark.
Headquarters
Denmark
Address
Sydmarken 11, Soeborg, 2860
Website
www.zealandpharma.com
Telephone
45 88773600
No of Employees
253
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZEAL (CPH)
Revenue (2022)
$49.8M
229.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
41.5%
(2022 vs 2021)
Market Cap*
$5.4B
Net Profit Margin (2022)
XYZ
82.2%
(2022 vs 2021)
* As of and is in US$
Zealand Pharma AS premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Glepaglutide: Short Bowel Syndrome |
| Dasiglucagon: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Financing Agreements | In December, the company signed a finance agreement with the European Investment Bank to secure a loan facility of EUR90 million. |
| 2023 | Others | In June, the company announced the submission of a new drug application to the US Food and Drug Administration (FDA) for dasiglucagon for the prevention and treatment of low blood sugar (hypoglycemia) in pediatric patients 7 days of age or older with congenital hyperinsulinism. |
| 2022 | Contracts/Agreements | In September, the company entered into a global license and development agreement with Novo Nordisk to commercialize ZEGALOGUE (dasiglucagon) for injection. |
Competitor Comparison
| Key Parameters | Zealand Pharma AS | Bavarian Nordic AS | Ascendis Pharma AS | Cyclenium Pharma Inc | Forward Pharma AS |
|---|---|---|---|---|---|
| Headquarters | Denmark | Denmark | Denmark | Canada | Denmark |
| City | Soeborg | Hellerup | Hellerup | Montreal | Hellerup |
| State/Province | - | - | - | Quebec | - |
| No. of Employees | 253 | 1,379 | 879 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Martin Nicklasson | Chairman | Executive Board | 2015 | 68 |
| Kirsten A. Drejer | Vice Chairman | Executive Board | 2018 | 67 |
| Adam Steensberg | President; Chief Executive Officer | Senior Management | 2022 | 49 |
| Henriette Wennicke | Executive Vice President; Chief Financial Officer | Senior Management | 2022 | 40 |
| Ivan Moller | Chief Operating Officer; Executive Vice President | Senior Management | 2018 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward